{"id":146,"date":"2025-05-16T15:11:00","date_gmt":"2025-05-16T15:11:00","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=146"},"modified":"2026-09-07T18:51:27","modified_gmt":"2026-09-07T18:51:27","slug":"yk-11-research-compound-overview","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/yk-11-research-compound-overview\/","title":{"rendered":"YK-11: Research Compound Overview"},"content":{"rendered":"<p>Looking for <a href=\"https:\/\/lotilabs.com\/buy\/yk-11\/\" rel=\"noopener noreferrer\" target=\"_self\">YK 11<\/a> for your research? We recommend readers do their own research and use YK-11 for research purposes only.<\/p>\n<div class=\"ez-toc-v2_0_81 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\" id=\"ez-toc-container\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<p><span class=\"ez-toc-title-toggle\"><a aria-label=\"Toggle Table of Content\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" href=\"#\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg class=\"list-377408\" fill=\"none\" height=\"20px\" style=\"fill: #999;color:#999\" viewbox=\"0 0 24 24\" width=\"20px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg baseprofile=\"tiny\" class=\"arrow-unsorted-368013\" height=\"10px\" style=\"fill: #999;color:#999\" version=\"1.2\" viewbox=\"0 0 24 24\" width=\"10px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"><\/path><\/svg><\/span><\/span><\/span><\/a><\/span><\/p><\/div>\n<nav>\n<ul class=\"ez-toc-list ez-toc-list-level-1\">\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lotilabs.com\/resources\/?p=146\/#What_is_YK-11\">What is YK-11?<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lotilabs.com\/resources\/?p=146\/#How_Does_YK-11_Work\">How Does YK-11 Work?<\/a><\/li>\n\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lotilabs.com\/resources\/?p=146\/#Safety_Precautions\">Safety Precautions<\/a><\/li>\n\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lotilabs.com\/resources\/?p=146\/#Stacking_and_Combination\">Stacking and Combination<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/lotilabs.com\/resources\/?p=146\/#Why_Choose_Loti_Labs_for_YK-11\">Why Choose Loti Labs for YK-11?<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/lotilabs.com\/resources\/?p=146\/#Product_Information\">Product Information<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/lotilabs.com\/resources\/?p=146\/#Buy_YK-11_Online\">Buy YK-11 Online<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/lotilabs.com\/resources\/?p=146\/#FAQs\">FAQs<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/lotilabs.com\/resources\/?p=146\/#References\">References<\/a><\/li>\n<\/ul>\n<\/nav>\n<\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_YK-11\"><\/span><span class=\"ez-toc-section\" id=\"What_is_YK-11\"><\/span><span class=\"ez-toc-section\" id=\"What_is_YK-11\"><\/span><span class=\"ez-toc-section\" id=\"What_is_YK-11\"><\/span>What is <a href=\"https:\/\/lotilabs.com\/buy\/yk-11\/\" rel=\"noopener noreferrer\" target=\"_self\">YK-11<\/a>?<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Although it has steroid-like properties, YK-11 is not a steroid. YK-11 is used strictly for research purposes and is not approved for human consumption.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_Does_YK-11_Work\"><\/span><span class=\"ez-toc-section\" id=\"How_Does_YK-11_Work\"><\/span><span class=\"ez-toc-section\" id=\"How_Does_YK-11_Work\"><\/span><span class=\"ez-toc-section\" id=\"How_Does_YK-11_Work\"><\/span>How Does <a href=\"https:\/\/lotilabs.com\/buy\/yk-11\/\" rel=\"noopener noreferrer\" target=\"_self\">YK-11<\/a> Work?<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Stacking_and_Combination\"><\/span><span class=\"ez-toc-section\" id=\"Stacking_and_Combination\"><\/span><span class=\"ez-toc-section\" id=\"Stacking_and_Combination\"><\/span><span class=\"ez-toc-section\" id=\"Stacking_and_Combination\"><\/span>Stacking and Combination<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Follistatin_Myostatin_Inhibition_The_Research_Mechanism\"><\/span><span class=\"ez-toc-section\" id=\"Follistatin_Myostatin_Inhibition_The_Research_Mechanism\"><\/span><span class=\"ez-toc-section\" id=\"Follistatin_Myostatin_Inhibition_The_Research_Mechanism\"><\/span><span class=\"ez-toc-section\" id=\"Follistatin_Myostatin_Inhibition_Mechanism\"><\/span>Follistatin &amp; Myostatin Inhibition: The Research Mechanism<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>YK11\u2019s most distinctive feature in preclinical research is its dual mechanism: partial agonism of the androgen receptor (AR) combined with upregulation of follistatin, a natural inhibitor of myostatin (GDF-8).<\/p>\n<h3 class=\"wp-block-heading\">How the Follistatin Pathway Works<\/h3>\n<p>In the Kanno et al. (2011, 2013) studies using C2C12 myoblast cell lines, YK11 was observed to:<\/p>\n<ul class=\"wp-block-list\">\n<li><strong>Upregulate follistatin expression<\/strong> via activation of the androgen receptor pathway<\/li>\n<li><strong>Inhibit myostatin (GDF-8) signaling<\/strong>, removing a key constraint on myogenic differentiation<\/li>\n<li><strong>Stimulate Follistatin-Like 3 (FSTL3)<\/strong>, a secondary myostatin antagonist extending the inhibitory effect<\/li>\n<li><strong>Activate Akt\/PKB phosphorylation<\/strong>, a downstream pathway linked to protein synthesis<\/li>\n<\/ul>\n<p>This mechanism differentiates YK11 from traditional SARMs, which act primarily through direct AR binding. The follistatin\/myostatin axis may explain why researchers classify YK11 as a potential \u201cmyostatin inhibitor\u201d \u2014 though this classification remains under scientific debate.<\/p>\n<p><em>All mechanistic data cited here derives from in vitro (cell culture) studies. No human trials have investigated these pathways in vivo as of 2026.<\/em><\/p>\n<div style=\"background:#f0f4ff;border:1px solid #c5d0f0;border-radius:12px;padding:28px 24px;margin:32px 0;font-family:system-ui,sans-serif;\">\n<p style=\"text-align:center;font-weight:700;font-size:14px;letter-spacing:.08em;text-transform:uppercase;color:#5a6a9a;margin:0 0 20px;\">YK11 Dual Mechanism Pathway (Preclinical Model)<\/p>\n<div style=\"display:flex;flex-direction:column;align-items:center;gap:0;\">\n<div style=\"background:#1e3a8a;color:#fff;border-radius:8px;padding:12px 28px;font-weight:600;font-size:15px;text-align:center;min-width:220px;\">YK11 (DHT Derivative)<\/div>\n<div style=\"color:#1e3a8a;font-size:22px;line-height:1;margin:4px 0;\">\u2193<\/div>\n<div style=\"background:#2563eb;color:#fff;border-radius:8px;padding:12px 28px;font-weight:600;font-size:15px;text-align:center;min-width:220px;\">Androgen Receptor (AR) Activation<\/div>\n<div style=\"color:#2563eb;font-size:22px;line-height:1;margin:4px 0;\">\u2193<\/div>\n<div style=\"display:flex;gap:16px;flex-wrap:wrap;justify-content:center;\">\n<div style=\"background:#3b82f6;color:#fff;border-radius:8px;padding:10px 20px;font-weight:600;font-size:14px;text-align:center;\">Follistatin \u2191<\/div>\n<div style=\"background:#3b82f6;color:#fff;border-radius:8px;padding:10px 20px;font-weight:600;font-size:14px;text-align:center;\">FSTL3 \u2191<\/div>\n<div style=\"background:#3b82f6;color:#fff;border-radius:8px;padding:10px 20px;font-weight:600;font-size:14px;text-align:center;\">Akt\/PKB \u2191<\/div>\n<\/div>\n<div style=\"color:#2563eb;font-size:22px;line-height:1;margin:4px 0;\">\u2193<\/div>\n<div style=\"background:#ef4444;color:#fff;border-radius:8px;padding:12px 28px;font-weight:600;font-size:15px;text-align:center;min-width:220px;\">Myostatin (GDF-8) Inhibition \u2193<\/div>\n<div style=\"color:#ef4444;font-size:22px;line-height:1;margin:4px 0;\">\u2193<\/div>\n<div style=\"background:#16a34a;color:#fff;border-radius:8px;padding:12px 28px;font-weight:600;font-size:15px;text-align:center;min-width:220px;\">Myogenic Differentiation (In Vitro)<\/div>\n<\/div>\n<p style=\"text-align:center;font-size:12px;color:#6b7280;margin:16px 0 0;\">Source: Kanno et al., 2011, 2013 \u2014 C2C12 myoblast cell line studies. No in vivo human data exists.<\/p>\n<\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pharmacokinetic_Profile_Steroidal_Structure_Half-Life\"><\/span><span class=\"ez-toc-section\" id=\"Pharmacokinetic_Profile_Steroidal_Structure_Half-Life\"><\/span><span class=\"ez-toc-section\" id=\"Pharmacokinetic_Profile_Steroidal_Structure_Half-Life\"><\/span><span class=\"ez-toc-section\" id=\"Pharmacokinetic_Profile_Half_Life\"><\/span>Pharmacokinetic Profile: Steroidal Structure &amp; Half-Life<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Unlike most SARMs (LGD-4033, RAD-140, Ostarine) which use non-steroidal scaffolds, YK11 is structurally derived from <strong>5\u03b1-dihydrotestosterone (DHT)<\/strong>. This distinction has significant pharmacokinetic implications that current research literature does not fully address \u2014 representing one of the most significant data gaps in YK11 research.<\/p>\n<h3 class=\"wp-block-heading\">Structural Properties<\/h3>\n<ul class=\"wp-block-list\">\n<li><strong>C17-alpha methyl ester modification:<\/strong> The ester group at C17 may affect hepatic first-pass metabolism differently than C17-alpha alkylated steroids<\/li>\n<li><strong>Molecular weight:<\/strong> 430.54 g\/mol (CAS: 1370003-76-1); Molecular formula: C<sub>25<\/sub>H<sub>34<\/sub>O<sub>6<\/sub><\/li>\n<li><strong>Steroidal backbone:<\/strong> More structurally similar to anabolic steroids than non-steroidal SARMs \u2014 potentially influencing SHBG binding and metabolic clearance<\/li>\n<li><strong>No published human pharmacokinetic data:<\/strong> Half-life estimates (commonly cited as ~6\u201312 hours) are extrapolated from structural analogy with DHT metabolites, not measured human data<\/li>\n<\/ul>\n<p>The gap between YK11\u2019s steroidal architecture and the complete absence of human pharmacokinetic studies is an unresolved limitation that distinguishes it from more extensively studied compounds in the SARM class.<\/p>\n<div style=\"background:#fafafa;border:1px solid #e5e7eb;border-radius:12px;padding:28px 24px;margin:32px 0;font-family:system-ui,sans-serif;\">\n<p style=\"text-align:center;font-weight:700;font-size:14px;letter-spacing:.08em;text-transform:uppercase;color:#6b7280;margin:0 0 20px;\">Research Evidence Level: YK11 vs RAD-140 (2026)<\/p>\n<div style=\"display:grid;grid-template-columns:1fr 1fr;gap:12px;max-width:560px;margin:0 auto;\">\n<div style=\"background:#1e3a8a;color:#fff;border-radius:6px;padding:8px 12px;text-align:center;font-weight:700;font-size:13px;\">YK11<\/div>\n<div style=\"background:#7c3aed;color:#fff;border-radius:6px;padding:8px 12px;text-align:center;font-weight:700;font-size:13px;\">RAD-140<\/div>\n<div style=\"background:#dbeafe;border-radius:6px;padding:8px 12px;font-size:13px;color:#1e3a8a;\">\u2705 In vitro (cell)<\/div>\n<div style=\"background:#ede9fe;border-radius:6px;padding:8px 12px;font-size:13px;color:#5b21b6;\">\u2705 In vitro (cell)<\/div>\n<div style=\"background:#dbeafe;border-radius:6px;padding:8px 12px;font-size:13px;color:#1e3a8a;\">\u2705 Rodent models<\/div>\n<div style=\"background:#ede9fe;border-radius:6px;padding:8px 12px;font-size:13px;color:#5b21b6;\">\u2705 Rodent models<\/div>\n<div style=\"background:#fee2e2;border-radius:6px;padding:8px 12px;font-size:13px;color:#991b1b;\">\u274c Human PK data<\/div>\n<div style=\"background:#ede9fe;border-radius:6px;padding:8px 12px;font-size:13px;color:#5b21b6;\">\u2705 Phase I PK data<\/div>\n<div style=\"background:#fee2e2;border-radius:6px;padding:8px 12px;font-size:13px;color:#991b1b;\">\u274c Clinical trials<\/div>\n<div style=\"background:#ede9fe;border-radius:6px;padding:8px 12px;font-size:13px;color:#5b21b6;\">\u2705 Phase II (ongoing)<\/div>\n<div style=\"background:#dbeafe;border-radius:6px;padding:8px 12px;font-size:13px;color:#1e3a8a;\">\u2705 Myostatin pathway<\/div>\n<div style=\"background:#fee2e2;border-radius:6px;padding:8px 12px;font-size:13px;color:#991b1b;\">\u274c Myostatin pathway<\/div>\n<\/div>\n<p style=\"text-align:center;font-size:12px;color:#6b7280;margin:16px 0 0;\">Evidence asymmetry as of 2026. Both compounds prohibited under WADA S1.2.<\/p>\n<\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Hippocampal_Neurochemistry_Emerging_2024%E2%80%932025_Research\"><\/span><span class=\"ez-toc-section\" id=\"Hippocampal_Neurochemistry_Emerging_2024%E2%80%932025_Research\"><\/span><span class=\"ez-toc-section\" id=\"Hippocampal_Neurochemistry_Emerging_2024%E2%80%932025_Research\"><\/span><span class=\"ez-toc-section\" id=\"Hippocampal_Neurochemistry_Research\"><\/span>Hippocampal Neurochemistry: Emerging 2024\u20132025 Research<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Research from 2024\u20132025 studying AR-active DHT-derived compounds suggests potential modulation of:<\/p>\n\n<p>Critically, YK11\u2019s <em>partial<\/em> agonism profile means CNS effects are not predictable from full-agonist testosterone data.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"WADA_2026_Regulatory_Classification\"><\/span><span class=\"ez-toc-section\" id=\"WADA_2026_Regulatory_Classification\"><\/span><span class=\"ez-toc-section\" id=\"WADA_2026_Regulatory_Classification\"><\/span><span class=\"ez-toc-section\" id=\"WADA_Regulatory_Classification_2026\"><\/span>WADA 2026 Regulatory Classification<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>YK11 is classified under the World Anti-Doping Agency (WADA) 2026 Prohibited List as a <strong>non-approved anabolic agent<\/strong> (Section S1.2 \u2014 Other Anabolic Agents). This classification has been in effect since the early 2020s.<\/p>\n<figure class=\"wp-block-table\">\n<table>\n<thead>\n<tr>\n<th>Jurisdiction<\/th>\n<th>Classification<\/th>\n<th>Current Status<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>WADA (International)<\/td>\n<td>Prohibited \u2014 S1.2 Other Anabolic Agents<\/td>\n<td>Banned in competitive sport (2026)<\/td>\n<\/tr>\n<tr>\n<td>United States (FDA)<\/td>\n<td>Not approved for human use; not a federally scheduled substance<\/td>\n<td>Research use only<\/td>\n<\/tr>\n<tr>\n<td>Canada (Health Canada)<\/td>\n<td>Not an approved drug; enforcement warnings issued 2022\u20132024<\/td>\n<td>Unapproved therapeutic<\/td>\n<\/tr>\n<tr>\n<td>Australia (TGA)<\/td>\n<td>Schedule 4 when compounded for prescription use<\/td>\n<td>Regulated<\/td>\n<\/tr>\n<tr>\n<td>United Kingdom<\/td>\n<td>Not controlled under the Misuse of Drugs Act 1971<\/td>\n<td>Research chemical<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n<p>As of 2026, there are no registered clinical trials for YK11 in humans on ClinicalTrials.gov. The compound remains exclusively in the preclinical research phase, with all published mechanistic data from in vitro and rodent model studies.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"YK11_vs_RAD-140_Research_Profile_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"YK11_vs_RAD-140_Research_Profile_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"YK11_vs_RAD-140_Research_Profile_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"YK11_vs_RAD140_Research_Comparison\"><\/span>YK11 vs RAD-140: Research Profile Comparison<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A frequent research question is how YK11 compares mechanistically to RAD-140 (Testolone). The two compounds differ significantly in chemical origin, mechanism, and evidence base.<\/p>\n<figure class=\"wp-block-table\">\n<table>\n<thead>\n<tr>\n<th>Parameter<\/th>\n<th>YK11<\/th>\n<th>RAD-140 (Testolone)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Chemical class<\/strong><\/td>\n<td>Steroidal (DHT derivative)<\/td>\n<td>Non-steroidal (SARM)<\/td>\n<\/tr>\n<tr>\n<td><strong>Primary mechanism<\/strong><\/td>\n<td>Partial AR agonist + Follistatin upregulation<\/td>\n<td>Full selective AR partial agonist<\/td>\n<\/tr>\n<tr>\n<td><strong>Myostatin inhibition<\/strong><\/td>\n<td>Yes \u2014 via follistatin\/FSTL3 pathway<\/td>\n<td>No direct myostatin pathway<\/td>\n<\/tr>\n<tr>\n<td><strong>Osteogenic activity<\/strong><\/td>\n<td>Yes \u2014 osteoblast stimulation observed in vitro<\/td>\n<td>Minimal bone-specific data<\/td>\n<\/tr>\n<tr>\n\n<td>Limited; hippocampal interactions emerging (2024\u20132025)<\/td>\n\n<\/tr>\n<tr>\n<td><strong>Human clinical trials<\/strong><\/td>\n<td>None (0 registered ClinicalTrials.gov entries)<\/td>\n<td>Phase I completed; Phase II ongoing (breast cancer, 2025\u20132026)<\/td>\n<\/tr>\n<tr>\n<td><strong>WADA status (2026)<\/strong><\/td>\n<td>Prohibited \u2014 S1.2<\/td>\n<td>Prohibited \u2014 S1.2<\/td>\n<\/tr>\n<tr>\n<td><strong>HPG axis suppression<\/strong><\/td>\n<td>Likely \u2014 AR agonism + steroidal structure both contribute<\/td>\n<td>Documented in Phase I human trial data<\/td>\n<\/tr>\n<tr>\n<td><strong>Liver safety data<\/strong><\/td>\n<td>No human data; steroidal C17 modification raises monitoring consideration<\/td>\n<td>No major hepatotoxicity signal in Phase I<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n<p>The critical asymmetry: RAD-140 has progressed to human clinical trials, providing actual safety and pharmacokinetic data. YK11 has no equivalent human data \u2014 a fundamental evidence gap that should be considered when evaluating these compounds for research purposes.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_Choose_Loti_Labs_for_YK-11\"><\/span><span class=\"ez-toc-section\" id=\"Why_Choose_Loti_Labs_for_YK-11\"><\/span><span class=\"ez-toc-section\" id=\"Why_Choose_Loti_Labs_for_YK-11\"><\/span><span class=\"ez-toc-section\" id=\"Why_Choose_Loti_Labs_for_YK-11\"><\/span>Why Choose Loti Labs for YK-11?<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Loti Labs is a trusted provider of high-quality research compounds at competitive prices. Many customers have given positive feedback and trust Loti Labs as a reliable supplier.<\/p>\n<p>They offer third-party testing, Certificates of Analysis, fast shipping, and excellent customer service, making them a preferred choice for researchers. Loti Labs has a good reputation in the research compound market for quality and reliability.<\/p>\n<p>YK-11 is in stock to fulfill all customer orders.<\/p>\n<h3 class=\"wp-block-heading\">Quality Control<\/h3>\n<p>Each batch of YK-11 from Loti Labs is tested in an independent laboratory to verify purity and potency for research use.<\/p>\n<h3 class=\"wp-block-heading\">Customer Service<\/h3>\n<p>Loti Labs provides good customer support to help researchers with questions and make the purchasing process smooth.<\/p>\n<h3 class=\"wp-block-heading\">Pricing<\/h3>\n<p>Loti Labs offers competitive pricing with bulk discounts; YK-11 is affordable for research budgets.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Product_Information\"><\/span><span class=\"ez-toc-section\" id=\"Product_Information\"><\/span><span class=\"ez-toc-section\" id=\"Product_Information\"><\/span><span class=\"ez-toc-section\" id=\"Product_Information\"><\/span>Product Information<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul class=\"wp-block-list\">\n<li><strong>Form:<\/strong> Viscous, cloudy liquid<\/li>\n<li><strong>Concentration:<\/strong> 10 mg\/ml<\/li>\n<li><strong>Molecular Formula:<\/strong> C25H34O6<\/li>\n<li><strong>CAS Number:<\/strong> 1370003-76-1<\/li>\n<li><strong>Packaging:<\/strong> Available in 30 ml bottles of liquid or bottles with capsules<\/li>\n<li><strong>Availability:<\/strong> Liquid and capsule forms available<\/li>\n<\/ul>\n<p>YK-11 can be purchased for research purposes in many countries but is not for human consumption.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Buy_YK-11_Online\"><\/span><span class=\"ez-toc-section\" id=\"Buy_YK-11_Online\"><\/span><span class=\"ez-toc-section\" id=\"Buy_YK-11_Online\"><\/span><span class=\"ez-toc-section\" id=\"Buy_YK-11_Online\"><\/span>Buy YK-11 Online<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>You can order YK-11 online at <a href=\"https:\/\/lotilabs.com\" rel=\"noopener noreferrer\" target=\"_self\">https:\/\/lotilabs.com<\/a>. YK-11 is in stock for fast shipping. They offer quality products, good customer service, and competitive pricing for research.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><span class=\"ez-toc-section\" id=\"FAQs\"><\/span>FAQs<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3 class=\"wp-block-heading\">What is YK-11 and how is it classified?<\/h3>\n<p>YK-11 is a synthetic SARM and myostatin inhibitor used in research. It is not a steroid but shows some steroid-like properties in lab studies.<\/p>\n<h3 class=\"wp-block-heading\">How does YK-11 work in research studies?<\/h3>\n\n<h3 class=\"wp-block-heading\">Why choose Loti Labs for YK-11?<\/h3>\n<p>Loti Labs provides high-quality research materials with third-party testing, competitive pricing, and good customer support for consistency and reliability in research.<\/p>\n<h3 class=\"wp-block-heading\">What are the product specifications of YK-11 from Loti Labs?<\/h3>\n<p>YK-11 is supplied in 30 ml bottles with a concentration of 10 mg\/ml, viscous and cloudy in appearance, molecular formula C25H34O6, and CAS Number 1370003-76-1.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"References\"><\/span>References<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ol class=\"wp-block-list\">\n<li>Kahn, B. B., &amp; Flier, J. S. (2000). J Clin Invest, 106, 473-481. doi:10.1172\/JCI10842<\/li>\n<li>Lee, S. J., &amp; McPherron, A. C. (2001). Proc Natl Acad Sci U S A, 98, 9306-9311. doi:10.1073\/pnas.151270098<\/li>\n<li>Schuelke, M., et al. (2004). N Engl J Med, 350, 2682-2688. doi:10.1056\/NEJMoa0409334<\/li>\n<li>Zhao, B., Wall, R. J., &amp; Yang, J. (2005). Biochem Biophys Res Commun, 337, 248-255. doi:10.1016\/j.bbrc.2005.08.1867<\/li>\n<li>McPherron, A. C., Lawler, A. M., &amp; Lee, S. J. (1997). Nature, 387, 83-90. doi:10.1038\/387083a0<\/li>\n<li>Grobet, L., et al. (1997). A myostatin mutation associated with double muscling in cattle. Nat Genet, 17, 71-74. doi:10.1038\/ng0997-71<\/li>\n<\/ol>\n\n","protected":false},"excerpt":{"rendered":"<p>Looking for YK 11 for your research? We recommend readers do their own research and use YK-11 for research purposes only. Table of Contents Toggle What is YK-11? How Does YK-11 Work? [\u2026]\n","protected":false},"author":1,"featured_media":150,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-146","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"_links":{"self":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/comments?post=146"}],"version-history":[{"count":0,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/146\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media\/150"}],"wp:attachment":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media?parent=146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/categories?post=146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/tags?post=146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}